tradingkey.logo
tradingkey.logo
検索

Organon & Co

OGN
ウォッチリストに追加
13.475USD
+0.025+0.19%
終値 06/24, 16:00ET15分遅れの株価
3.50B時価総額
14.27直近12ヶ月PER

詳細情報 Organon & Co 企業名

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Coの企業情報

企業コードOGN
会社名Organon & Co
上場日May 14, 2021
最高経営責任者「CEO」Morrissey (Joseph T)
従業員数10000
証券種類Ordinary Share
決算期末May 14
本社所在地30 Hudson Street
都市JERSEY CITY
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号07302
電話番号15514306000
ウェブサイトhttps://www.organon.com/
企業コードOGN
上場日May 14, 2021
最高経営責任者「CEO」Morrissey (Joseph T)

Organon & Coの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Cynthia M. Patton
Ms. Cynthia M. Patton
Independent Director
Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--

よくある質問

Organon & Coの上位5名の株主は誰ですか?

Organon & Coの上位5名の株主は以下のとおりです。Mr. Matthew M. (Matt) Walsh

Organon & Co(OGN)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Organon & Coの株式を保有している機関は1398社あり、保有株式の総市場価値は約239.27Mで、全体の91.12%を占めています。2025Q4と比較して、機関の持ち株は-3985201.00増加しています。

Organon & Coの最大の収益源は何ですか?

2026Q1において、Women’s Health部門がOrganon & Coにとって最大の収益を生み出しており、その金額は1.75Bで、全収益の28.19%を占めています。
KeyAI